Loop Capital Downgrades JOANN to Hold, Lowers Price Target to $8
Loop Capital analyst Laura Champine downgrades JOANN (NASDAQ:JOAN) from Buy to Hold and lowers the price target from $10 to $8.
5 Short Squeeze Candidates To Watch This Week: TherapeuticsMD Tops List While This Arts And Crafts Retailer Joins The Leaderboard
Potential short squeeze plays gained steam in 2021, with new retail traders looking for the next huge move.
Mid-Afternoon Market Update: Skillsoft Falls After Q1 Results; Applied UV Shares Spike Higher
U.S. stocks traded lower toward the end of trading, with the Nasdaq Composite falling more than 1% on Thursday.
Mid-Day Market Update: Dow Drops 150 Points; Bluejay Diagnostics Shares Jump
U.S. stocks traded lower midway through trading, with the Dow Jones dropping 150 points on Thursday.
10 Biggest Price Target Changes For Monday
Citigroup cut PVH Corp. (NYSE: PVH) price target from $94 to $73. PVH shares fell 0.7% to close at $71.96 on Friday.
Piper Sandler Maintains Neutral on JOANN, Lowers Price Target to $6
Piper Sandler analyst Peter Keith maintains JOANN (NASDAQ:JOAN) with a Neutral and lowers the price target from $11 to $6.
Barclays Maintains Underweight on JOANN, Lowers Price Target to $5
Barclays analyst Adrienne Yih maintains JOANN (NASDAQ:JOAN) with a Underweight and lowers the price target from $9 to $5.
69 Biggest Movers From Friday
Gainers
Turning Point Therapeutics, Inc. (NASDAQ: TPTX) shares climbed 118.4% to close at $74.59 on Friday after Bristol Myers Squibb announced it will acquire Turning Point Therapeutics for $76 per share.
The ‘Sticky’ Challenges Driving This Joann Analyst’s Downgrade
Joann Inc. (NASDAQ: JOAN) reported disappointing results and its first-quarter print indicated that some challenges are likely to be “sticky,” according to BofA Securities.